<DOC>
	<DOCNO>NCT00130234</DOCNO>
	<brief_summary>This study do find drug call Xolair ( omalizumab ) , anti-IgE antibody , safe effective people chronic urticaria ( hive ) persistent symptom spite take antihistamine .</brief_summary>
	<brief_title>Effect Anti-IgE Chronic Urticaria</brief_title>
	<detailed_description>Omalizumab ( XolairÂ® ) recombinant humanize monoclonal antibody bind specifically FcEpsilonR1 bind site human IgE . The binding omalizumab inhibits ability IgE bind basophil mast cell . Free IgE level fall 89 % 98 % 16 24 week therapy respectively ( Busse , 2001 ) . Total IgE level rise patient treat omalizumab though almost IgE bound thus inactive . Omalizumab also show decrease expression FcEpsilonR1 receptor basophils mast cell ( Beck et al , 2004 ) . Omalizumab recently receive FDA approval treatment moderate severe persistent allergic asthma pediatric ( 12 year age ) adult patient . Studies also show efficacy treatment allergic rhinitis similar anti-IgE compound efficacious food allergy therapeutic ( Casale , 2001 , Leung 2003 ) . Given efficacy omalizumab treatment moderate severe allergic asthma , researcher conduct double-blind study evaluate safety efficacy omalizumab small number patient chronic urticaria persistent symptom spite background antihistamine therapy . Omalizumab currently indicate patient chronic urticaria . The primary hypothesis omalizumab lead reduction serum IgE level blood basophil high affinity IgE receptor expression subject chronic idiopathic urticaria . Additionally , clinical outcome quality life , symptoms score , medication use explore . This study allow understand role IgE play chronic urticaria .</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Males nonpregnant , nonbreastfeeding female Chronic urticaria define symptom &gt; 50 % day 3 day per week 12 week History angioedema Chronic daily therapy antihistamine stable dos antihistamine least 4 week . High baseline score pruritis ( least 2 3 point scale ) No etiology identify chronic urticaria drugrelated physical urticaria determine history , physical examination laboratory study Concomitant use systemic corticosteroid 1 month prior enrollment . Topical steroid use permit , inhaled topical steroid allow . Current use immunosuppressive medication ( cyclosporine , IVIg , methotrexate , cyclophosphamide ) . Any medication discontinue least 6 week screen . Treatment investigational agent within 30 day screen Previous treatment omalizumab Recent history drug alcohol abuse ( within 3 year prior study ) Active atopic dermatitis require use topical steroid agent Clinically relevant cardiovascular , hepatic , neurologic , psychiatric , endocrine , major systemic disease make protocol interpretation study result difficult .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>urticaria</keyword>
	<keyword>hive</keyword>
	<keyword>Xolair</keyword>
</DOC>